论文部分内容阅读
目的:探讨喉癌患者中耐药基因P糖蛋白(P-gp),谷胱苷肽-S转移酶(GST-π),DNA拓扑异构酶Ⅱ(TopoⅡ),胸苷酸合成酶(TS)表达的临床意义。方法:用免疫组化方法检测72例喉癌组织中的P-gp、GST-π、TopoⅡ和TS,分析其与临床病理资料及预后的相关性。结果:72例喉癌患者中,P-gp阳性66例、GST-π阳性50例、TopoⅡ阳性28例、TS阳性12例。P-gp的表达与病理分型、临床分期、淋巴转移及局部复发均相关,GST-π、TopoⅡ的表达与淋巴结转移相关,TS的表达与各项指标均无明显相关性。患者的病理分级、临床分期、术后是否复发及GST-π的表达均与术后生存时间明显相关。结论:喉癌患者P-gp、TopoⅡ、GST-π、TS的联合检测十分必要,病理分级、临床分期、术后复发及GST-π可以作为判断喉癌患者预后的指标。
Objective: To investigate the expression of P-gp, GST-π, TopoⅡ, thymidylate synthase (TS) in patients with laryngeal cancer ) Clinical significance of expression. Methods: The expressions of P-gp, GST-π, TopoⅡ and TS in 72 cases of laryngeal carcinoma were detected by immunohistochemistry, and their correlations with clinicopathological parameters and prognosis were analyzed. Results: Of the 72 laryngeal cancer patients, 66 were positive for P-gp, 50 were for GST-π, 28 were Topo II, and 12 were TS. The expression of P-gp was correlated with pathological type, clinical stage, lymphatic metastasis and local recurrence. The expression of GST-π, TopoⅡ was correlated with lymph node metastasis. The expression of TS was not correlated with each index. The pathological grade, clinical stage, recurrence and GST-π expression of patients were significantly correlated with postoperative survival time. Conclusion: The combined detection of P-gp, TopoⅡ, GST-π and TS in laryngeal cancer patients is very necessary. The pathological grade, clinical stage, postoperative recurrence and GST-π can be used as indexes to judge the prognosis of laryngeal cancer patients.